Core Viewpoint - The company TianKang (301263.SZ) announced that its subsidiary Jiangsu BoChuangYuan Biopharmaceutical Technology Co., Ltd. has received the Clinical Trial Approval Notice from the National Medical Products Administration, allowing the initiation of a seamless Phase II/III clinical trial for CKBA cream for the treatment of rosacea [1] Group 1 - The approval is significant as it marks a step forward in the clinical development of CKBA cream [1] - The clinical trial will focus on the indication of rosacea, which is a common skin condition [1] - This development may enhance the company's product pipeline and potential market offerings in the biopharmaceutical sector [1]

Core Viewpoint - The company, Taiankang (301263.SZ), has received approval from the National Medical Products Administration for a clinical trial of its drug CKBA for the treatment of rosacea, marking a significant advancement in its product pipeline [1]. Group 1: Clinical Trial Approval - Taiankang's subsidiary, Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., has been granted a Clinical Trial Approval Notice for CKBA, allowing it to conduct a seamless adaptive clinical trial for the II/III phase [1]. - The approval is specifically for the indication of rosacea, which indicates the company's focus on dermatological conditions [1]. Group 2: Drug Characteristics - CKBA is a small molecule drug derived from the active ingredient of traditional Chinese medicine, frankincense, optimized through structural modification [1]. - The drug possesses a novel structure, independent intellectual property rights, a clear mechanism of action, and good safety profile [1]. Group 3: Mechanism of Action - CKBA directly targets and inhibits key enzymes ACC1 and ACC2 involved in the synthesis and metabolism of long-chain fatty acids [1]. - It regulates the differentiation of naive CD4+ T cells into Th17 cells, significantly downregulating IL-17A expression and reducing inflammatory cell infiltration [1]. - This mechanism aims to improve the typical inflammatory response and erythema associated with rosacea [1].

泰恩康（301263）(301263.SZ)公告，公司控股子公司江苏博创园生物医药科技有限公司(简称"博创园") 收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意CKBA乳膏玫瑰痤疮适应症开展 II/III期无缝适应性临床试验。 ...

Core Viewpoint - The company, Taiankang (301263.SZ), has received approval from the National Medical Products Administration for a seamless Phase II/III clinical trial of CKBA cream for the treatment of rosacea [1] Company Summary - The company's subsidiary, Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan"), is responsible for the clinical trial of CKBA [1] - CKBA is a small molecule drug derived from the active ingredient of traditional Chinese medicine, myrrh, which has undergone structural modification and optimization [1] - The drug possesses a novel structure, independent intellectual property rights, a clear mechanism of action, and good safety profile [1] Mechanism of Action - CKBA directly targets and inhibits key enzymes ACC1 and ACC2 involved in the synthesis and metabolism of long-chain fatty acids [1] - It regulates the differentiation of naive CD4+ T cells into Th17 cells, significantly downregulating IL-17A expression and reducing inflammatory cell infiltration [1] - This mechanism helps to improve the typical inflammatory response and erythema associated with rosacea [1]

Core Viewpoint - The announcement indicates that Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., a subsidiary of Tiancong, has received approval from the National Medical Products Administration for a seamless adaptive clinical trial of CKBA ointment for the treatment of rosacea, marking a significant step in the development of innovative therapies in the pharmaceutical industry [1] Group 1 - The clinical trial approval is for the II/III phase of the CKBA ointment, which is a locally applied formulation developed independently by Bochuangyuan [1] - CKBA ointment is classified as a Class 1 innovative chemical drug, featuring a novel structure, independent intellectual property rights, a clear mechanism of action, and good safety profile [1] - The company aims to initiate the clinical trial as soon as possible, and if approved, the product could provide innovative and safe treatment options for patients, highlighting its social significance and economic value [1]

证券代码：301263 证券简称：泰恩康 公告编号：2025-068 广东泰恩康医药股份有限公司 关于控股子公司 CKBA 乳膏玫瑰痤疮适应症获得药物 临床试验批准通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于 2025 年 7 月 18 日 在巨潮资讯网（http://www.cninfo.com.cn）披露了《关于控股子公司 CKBA 乳 膏玫瑰痤疮适应症申报新药临床试验取得受理通知书的公告》（公告编号： 2025-046）。近日，公司控股子公司江苏博创园生物医药科技有限公司（以下 简称"博创园"）收到国家药品监督管理局签发的《药物临床试验批准通知 书》，同意 CKBA 乳膏玫瑰痤疮适应症开展 II/III 期无缝适应性临床试验。现 将相关情况公告如下： 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 7 月 18 日受理的 CKBA 乳膏临床试验申请符合药品注册的有关要求，同意本品 开展临床试验。申请的适应症：拟用于治疗玫瑰痤疮。 二、适应症相关情况简介 玫瑰痤疮是一种 ...

Core Viewpoint - The stock of TianKang has experienced a significant increase of 127.57% year-to-date, but has recently faced a decline in the short term, with a drop of 7.09% over the last five trading days [1] Group 1: Stock Performance - As of September 25, TianKang's stock price was 33.66 CNY per share, with a market capitalization of 14.322 billion CNY [1] - The stock has seen a net outflow of main funds amounting to 5.3094 million CNY, with large orders buying 18.7867 million CNY and selling 21.0756 million CNY [1] - Over the last 20 days, the stock has decreased by 4.62%, and over the last 60 days, it has decreased by 9.39% [1] Group 2: Company Overview - TianKang Pharmaceutical Co., Ltd. was established on January 22, 1999, and went public on March 29, 2022 [1] - The company operates in the pharmaceutical sector, focusing on the agency operation, research and development, production, and sales of pharmaceutical products, medical devices, and health materials [1] - The revenue composition includes 65.16% from pharmaceutical agency, 31.70% from pharmaceutical manufacturing, 2.97% from pharmaceutical technology services and technology transfer, and 0.17% from other sources [1] Group 3: Financial Performance - For the first half of 2025, TianKang reported a revenue of 347 million CNY, a year-on-year decrease of 12.23%, and a net profit attributable to shareholders of 37.0848 million CNY, down 56.75% year-on-year [2] - Since its A-share listing, the company has distributed a total of 460 million CNY in dividends, with 377 million CNY distributed over the past three years [3] Group 4: Shareholder Information - As of June 30, the number of shareholders for TianKang was 10,900, a decrease of 33.05% from the previous period [2] - The average number of circulating shares per shareholder increased by 49.36% to 27,747 shares [2]

Group 1 - The core viewpoint of the news is that 泰恩康's stock has experienced a significant decline recently despite a substantial increase in its price year-to-date, indicating potential volatility in the market [1][2]. - As of September 23, 泰恩康's stock price was 33.84 yuan per share, with a market capitalization of 14.399 billion yuan [1]. - The company has seen a year-to-date stock price increase of 128.79%, but it has declined by 12.42% over the last five trading days [1]. Group 2 - 泰恩康's main business segments include pharmaceutical agency (65.16%), pharmaceutical manufacturing (31.70%), and pharmaceutical technology services (2.97%) [1]. - As of June 30, the number of shareholders decreased by 33.05% to 10,900, while the average circulating shares per person increased by 49.36% to 27,747 shares [2]. - For the first half of 2025, 泰恩康 reported a revenue of 347 million yuan, a year-on-year decrease of 12.23%, and a net profit of 37.084 million yuan, down 56.75% year-on-year [2]. Group 3 - Since its A-share listing, 泰恩康 has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3].

据悉，泰恩康于2025年8月先后召开董事会、监事会及临时股东大会，审议通过2025年员工持股计划相 关议案，为计划落地奠定坚实基础。截至2025年9月22日，该计划通过二级市场集中竞价方式，累计买 入公司股票539.6243万股，占公司总股本的1.27%，成交总金额近1.98亿元（不含交易费用），成交均 价36.69元/股，实际认购份额严格控制在股东大会审议通过的上限范围内，操作合规且高效。 泰恩康此次员工持股计划的顺利落地，极大激发了创新活力与奋斗激情，为后续业务拓展、技术创新注 入更强动力。该计划的成功实施，有望成为驱动泰恩康实现新一轮高质量发展的新引擎。 此次员工持股计划覆盖公司（含控股子公司）董事、高级管理人员、核心骨干员工等关键群体，核心员 工以真金白银积极"加仓"公司股票，其行动本身即是对公司管理团队、核心竞争力和长远发展蓝图投下 的最有力"信任票"。根据公告，本次员工持股计划所购股票锁定期为12个月，自2025年9月22日起至 2026年9月21日止。 中证报中证网讯（王珞）9月22日，泰恩康（301263）（301263）发布公告，宣布公司2025年员工持股 计划已顺利完成股票购买，充分彰显对 ...

此次员工持股计划覆盖公司（含控股子公司）董事、高级管理人员、核心骨干员工等关键群体，核心员 工以真金白银积极"加仓"公司股票。根据公告，本次员工持股计划所购股票锁定期为12个月，自2025年 9月22日起至2026年9月21日止。 本报讯 （记者王镜茹）9月22日，广东泰恩康医药股份有限公司（以下简称"泰恩康"）发布公告，宣布 公司2025年员工持股计划已顺利完成股票购买，充分彰显对未来经营发展的坚定信心。 据悉，泰恩康于8月先后召开董事会、监事会及临时股东大会，审议通过2025年员工持股计划相关议 案，为计划落地打下坚实基础。截至9月22日，该计划通过二级市场集中竞价方式，累计买入公司股票 539.6243万股，占公司总股本的1.27%，成交总金额近1.98亿元（不含交易费用），成交均价36.69元/ 股，实际认购份额严格控制在股东大会审议通过的上限范围内，操作合规且高效。 公司董事长郑汉杰表示："员工持股计划圆满落地，是公司'以人为本、共享发展'理念的生动实践。员 工对公司未来战略前景的高度认同与坚定信心，是公司最宝贵的财富和无形的驱动力。我们将持续聚焦 核心战略，提升经营效能，以更亮眼的成绩回报全体股东 ...